Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells

  • Authors:
    • Lihua Qiu
    • Changlin Zhou
    • Yun Sun
    • Wen Di
    • Erica Scheffler
    • Sarah Healey
    • Harold Wanebo
    • Nicola Kouttab
    • Wenming Chu
    • Yinsheng Wan
  • View Affiliations

  • Published online on: October 1, 2006     https://doi.org/10.3892/or.16.4.907
  • Pages: 907-913
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The molecular and cellular mechanism of the development of pancreatic cancer is under constant and intensive study, and yet the cure is still out of reach. While surgical treatment is optional, conventional chemotherapy or chemo-radiotherapy remains the best choice. Among others, paclitaxel is proven to be a popular and, to a certain extent, effective chemotherapy agent. We proposed that the combination of paclitaxel and membrane permeable ceramide would enhance the fatality of cancer cells, and reported that the combination increased cell death of both head and neck and leukemic cancer cells. In this study, we treated pancreatic cancer cells (L3.6 cells) with paclitaxel and ceramide at the concentrations of clinical relevance, and treatment was then followed up with an investigation of the molecular mechanism of the synergism of paclitaxel and ceramide. The results of Western blot analysis indicated that the combo synergistically induced ERK and JNK phosphorylation, but not p38 and Akt phosphorylation. We also found that the combination (combo) induced EGFR phosphorylation in a synergistic manner. Furthermore, we observed that paclitaxel, ceramide, or combo-induced EGFR phosphorylation was inhibited by EGFR inhibitor, PD153035, while paclitaxel, ceramide, or combo-induced JNK and ERK phosphorylation was blocked by EGFR inhibitor, PD153035 and ERK inhibitor, U126. Taken together, our results demonstrated that the combination of paclitaxel and ceramide synergistically induced pancreatic cancer cell death through differential activation of EGFR-mediated MAP kinases. EGFR and ERK inhibitors may further enhance the paclitaxel and ceramide effect.

Related Articles

Journal Cover

October 2006
Volume 16 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Qiu, L., Zhou, C., Sun, Y., Di, W., Scheffler, E., Healey, S. ... Wan, Y. (2006). Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncology Reports, 16, 907-913. https://doi.org/10.3892/or.16.4.907
MLA
Qiu, L., Zhou, C., Sun, Y., Di, W., Scheffler, E., Healey, S., Wanebo, H., Kouttab, N., Chu, W., Wan, Y."Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells". Oncology Reports 16.4 (2006): 907-913.
Chicago
Qiu, L., Zhou, C., Sun, Y., Di, W., Scheffler, E., Healey, S., Wanebo, H., Kouttab, N., Chu, W., Wan, Y."Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells". Oncology Reports 16, no. 4 (2006): 907-913. https://doi.org/10.3892/or.16.4.907